



OPEN ACCESS

EDITED BY

Teresa M. V. D. Pinho e Melo,
University of Coimbra, Portugal

REVIEWED BY

Roman Bielski,
Wilkes University, United States
Rajendra Rohokale,
University of Florida, United States

*CORRESPONDENCE

Nikolay E. Nifantiev,
✉ nen@ioc.ac.ru

RECEIVED 25 September 2024

ACCEPTED 23 October 2024

PUBLISHED 14 November 2024

CITATION

Dorokhova VS, Komarova BS, Previato JO,
Mendonça Previato L, Krylov VB and
Nifantiev NE (2024) Synthesis of branched and
linear galactooligosaccharides related to
glucuronoxylomannogalactan of
Cryptococcus neoformans.
Front. Chem. 12:1501766.
doi: 10.3389/fchem.2024.1501766

COPYRIGHT

© 2024 Dorokhova, Komarova, Previato,
Mendonça Previato, Krylov and Nifantiev. This is
an open-access article distributed under the
terms of the [Creative Commons Attribution
License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that the
original publication in this journal is cited, in
accordance with accepted academic practice.
No use, distribution or reproduction is
permitted which does not comply with these
terms.

Synthesis of branched and linear galactooligosaccharides related to glucuronoxylomannogalactan of *Cryptococcus neoformans*

Vera S. Dorokhova¹, Bozhena S. Komarova¹, José O. Previato²,
Lúcia Mendonça Previato², Vadim B. Krylov^{1,3} and
Nikolay E. Nifantiev^{1*}

¹Laboratory of Glycoconjugate Chemistry, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia, ²Laboratório de Glicobiologia, Instituto de Biofísica Carlos Chagas Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ³Laboratory of Synthetic Glycovaccines, N.D. Zelinsky Institute of Organic Chemistry, Russian Academy of Sciences, Moscow, Russia


This study focuses on the synthesis of a series of oligo- α -(1 \rightarrow 6)-D-galactopyranosides bearing β -D-galactofuranosyl residues at O-2 and/or O-3, which relate structurally to fragments of glucuronoxylomannogalactan (GXMGal) from the fungal pathogen *Cryptococcus neoformans* that causes severe diseases in immunocompromised patients. The preparation of target compounds is based on the use of a selectively O-protected N-phenyltrifluoroacetimidoyl galactopyranoside donor with an allyl group at O-2, levulinoyl group (Lev) at O-3, pentafluorobenzoyl (PFB) group at O-4, and fluorenylmethoxycarbonyl (Fmoc) group at O-6. The choice of protecting groups for this donor ensures the stereospecific formation of α -(1 \rightarrow 6)-glycosidic bonds due to the stereodirecting effect of acyls at O-3, O-4, and O-6. At the same time, this combination of O-substituents permits the selective recovery of free OH groups at O-2, O-3, and O-6 for chain elongation via the introduction of β -D-galactofuranosyl and α -D-galactopyranosyl residues. The reported compounds are obtained as aminopropyl glycosides, which are transformed into biotinylated conjugates for further use as coating antigens in immunological studies. The obtained oligosaccharides were subjected to detailed ¹³C NMR analysis to show the spatial similarity of the obtained hexasaccharide with the corresponding fragment in the GXMGal chain, making this compound suitable for further immunological studies of *C. neoformans*.

KEYWORDS

Cryptococcus neoformans, oligosaccharides, glucuronoxylomannogalactan, stereoselective glycosylation, orthogonal protecting groups

Introduction

Cryptococcus neoformans is a human fungal pathogen capable of causing severe diseases in patients with a weakened immune system (especially in patients with HIV/AIDS) (Bermas and Geddes-McAlister, 2020; Zhao et al., 2023). This fungus can attack the central nervous system, thus causing cryptococcal meningitis, a fatal disease if untreated (Chen et al., 2022). In recent years, serious concerns have arisen about the increasing cases of cryptococcal meningitis in HIV-seronegative individuals (Paccoud et al., 2023). This fungus can also attack the lungs, skin, and



other organs, which also leads to serious complications (Rivera et al., 1998). This pathogen spreads through bird droppings and enters the human body through inhaled dust (Maziarz and Perfect, 2016). *C. neoformans* is most commonly found in territories of Africa and Southern and Southeastern Asia, but the affected area is expanding every year (Rajasingham et al., 2022).

One of the main factors contributing to the virulence of *C. neoformans* is its bulk polysaccharide capsule (Vecchiarelli, 2000; Doering, 2009). It is composed mainly of glucuronoxylomannan (GXM), with minor components—glucuronoxylomannogalactan (GXMGal) and mannoprotein. The structure and immunological properties of GXM were studied in detail (Cherniak et al., 1998; McFadden and Casadevall, 2004; Oscarson et al., 2005; Nakouzi et al., 2009; Hargett et al., 2024), and their heterogeneity was shown for different serotypes. In contrast, the minor polysaccharide GXMGal of the *C. neoformans* capsule, which has not attracted significant attention until recently, is of great interest from an immunological point of view due to its immunomodulatory effect (Villena et al., 2008; Vecchiarelli et al., 2011; Decote-Ricardo et al., 2019). Unlike GXM (Cherniak et al., 1980; Skelton et al., 1991a; 1991b; James and Cherniak, 1992), GXMGal is a conserved polysaccharide that seems to be structurally similar in all *C. neoformans* serotypes studied to date (Cherniak et al., 1982; James and Cherniak, 1992; Vaishnav et al., 1998; Heiss et al., 2009).


Generally, GXMGal consists of a poly- α -(1 \rightarrow 6)-D-galactopyranan backbone bearing β -Xylp-(1 \rightarrow 3)- α -Manp-(1 \rightarrow 3)[β -Xylp-(1 \rightarrow 2)-] α -Manp-1 \rightarrow 4][β -GlcP-A-1 \rightarrow 3]- β -Galp and β -D-galactofuranosyl residues (Figure 1) (Heiss et al., 2013; Previato et al., 2017). However, *C. neoformans* GXMGal does not contain a regular and defined repeating unit due to the variable addition of β -GlcP, β -Xylp, and O-acetyl groups on the β -Galp side chains and a variable number of β -Galp branches on the polysaccharide backbone. Given the high immunological activity of galactofuranosyl-bearing epitopes demonstrated on a number of other polysaccharide antigens (Turco and Pedersen, 2003; Peltier et al., 2008; Richards and Lowary,

2009; Tefsen et al., 2012; Krylov et al., 2021; Argunov et al., 2024), we started the systematic synthesis of spacer-armed oligosaccharides related to GXMGal fragments bearing galactofuranosyl residues for their immunological studies toward the development of potential immunomodulators, diagnostic kits, and vaccines.

Previously (Dorokhova et al., 2021), we described the preparation, nuclear magnetic resonance (NMR), and conformational studies of the model trisaccharide with two β -D-galactofuranosyl residues at O-2 and O-3, which relates to branch point A (Figure 1), as well as of its constituent monofuranosylated disaccharides. In this study, we report on the synthesis and NMR studies of spacersaccharide 5a related to fragment B (Figure 1) of the GXMGal chain (Figure 1), which includes not only 2,3-vicinal branching but also 1,2-*cis*-pseudo-branching. These elements may influence the 3D structure of oligo and polysaccharides and, therefore, should be taken into account during the selection of the oligosaccharide, which is spatially equivalent to the target antigenic polysaccharide GXMGal. In addition to 5a, the synthesis of a series of its constituting oligosaccharide derivatives 1a–4a is also described, along with the preparation of corresponding biotinylated glycoconjugates 1b–5b required for use as molecular probes and coating antigens in a variety of immunological investigations (Figure 2).


Results and discussion

The galactopyranosyl units in target compounds have an α -anomeric configuration and, thus, are connected to other parts of the molecules through 1,2-*cis*-glycosidic bonds. Their stereoselective construction can be accomplished by the remote anchimeric assistance of remote acyl groups at O-3, O-4, and O-6 of the glycosyl donor. The stereocontrolling participation of a single acyl group, as well as the combined effect of two or three acyls, was previously applied for stereoselective 1,2-*cis*-glycosylation by gluco- and galacto-glycosyl donors [for reviews, see Nigudkar and



SCHEME 1

Synthesis of the monosaccharide donors **13** and **17** and acceptor **15**. Reagents and conditions: (i) FmocCl, 2,6-lutidine, MeCN, 2–3 days, 65% for **8** and 64% for **9**; (ii) LevOH, CMPI, DMAP, CH₂Cl₂, -18°C, 20 h, 87%; (iii) pentafluorobenzoyl chloride, Py, DMAP, 12 h, 82%; (iv) CAN, MeCN, benzene, H₂O, 0 °C, 10–12 min, 88% for **12** and 74% for **16**; (v) ClC(NPh)CF₃, K₂CO₃, acetone, 12 h, 82% for **13** and 84% for **17**; (vi) BzCl, Py, DMAP, CH₂Cl₂, 12 h, 99%; and (vii) piperidine, CH₂Cl₂, 0 °C, 15 min, 69%.



SCHEME 2

Regioselective removal of orthogonal-protecting groups in monosaccharide **11**. Reagents and conditions: (i) *N*-methylmorpholine, CH₂Cl₂, 2 days, 65%; (ii) NH₂NH₂·H₂O, AcOH, Py, 20 min, 96%; and (iii) [Ir(COD) (PMePh₂)₂]PF₆, H₂, I₂, THF, 2 h, 99%.


Monosaccharide blocks **15** and **17** were obtained based on 2-*O*-benzylated triol **7** (Zhu and Yang, 2012) (Scheme 1). Protecting groups (6-*O*-Fmoc and two benzoate groups at C-3 and C-4) were introduced sequentially with considerably high yields at each step. The resulting monosaccharide **14** was partially converted to acceptor **15** after Fmoc removal under the action of piperidine in tetrahydrofuran (THF). Hemiacetal **16** was also obtained from monosaccharide **14** and then treated with *N*-phenyltrifluoroacetimidoyl chloride in acetone. As in the case of donor **13**, chromatographic purification of the resulting 6-*O*-Fmoc-bearing donor was performed on neutral Al₂O₃, yielding compound **17** with a considerably high yield of 84%.

The conditions for the selective removal of the chosen protecting groups (Fmoc, Lev, and All) were optimized using the model monosaccharide **11** (Scheme 2). The use of the standard Fmoc-removal procedure in the piperidine/THF system led to a rapid cleavage of the Fmoc group (Pennington and Dunn, 1994; Werz, 2012). However, under these conditions, a side reaction was observed, which consisted of the substitution of a fluorine atom in 4-*O*-pentafluorobenzoate by piperidine. This process was


confirmed by HRMS data and the emergence of piperidine ring signals in ¹H NMR spectra at 3.31 ppm 1.65 ppm and ¹³C NMR at 52.1 ppm and 23.9 ppm, respectively. Thus, these conditions can be used only for compounds without a pentafluorobenzoyl group or only at the last synthetic steps of the complete deprotection. Nevertheless, the Fmoc group in the presence of pentafluorobenzoate was successfully removed under milder conditions under the action of *N*-methylmorpholine in methylene chloride for 2 days. The levulinoyl group was efficiently and selectively removed by hydrazine acetate in pyridine, resulting in compound **19** with a 96% yield. The allyl substituent at *O*-2 was selectively removed using (1,5-cyclooctadiene)bis(methyldiphenylphosphine)iridium(I) hexafluorophosphate ([Ir(COD) (PMePh₂)₂]PF₆), which was pre-reduced with hydrogen (Laroussarie et al., 2015). This resulted in compound **20** with an almost quantitative yield.

In order to increase the efficiency of the α-(1→6)-glycoside bond formation, the conditions for the glycosylation of the spacer-containing acceptor **21** by donor **13** were optimized. Originally, the coupling was carried out in the presence of trimethylsilyl trifluoromethane sulfonate

TABLE 1 Optimization of acceptor 21 glycosylation by donor 13.




Entry	Conditions	Yield of 23, % (α : β)
1	TMSOTf (0.8 eq), -35°C	28 (1 : 0)
2	TfOH (0.6 eq), CH_2Cl_2 , $-35^{\circ}\text{C} \rightarrow -15^{\circ}\text{C}$, then Et_3N	47 (1 : 0)
3	TfOH (0.6 eq), CH_2Cl_2 , -20°C , then NaHCO_3	64 (1 : 0)




(TMSOTf) at -35°C (Table 1, entry 1). The desired disaccharide **23** was obtained with an insufficient yield of 28%; however, full α -stereospecificity was achieved that can be explained by the presence of three α -directing protecting groups in donor **13**. The low yield may be attributed to the presence of three electron-withdrawing groups in

the donor, which lower its activity; hence, the side processes of its destruction occur before the glycosylation reaction is completed. An increase in the reaction yield to 47% was achieved by replacing the promoter with triflic acid, along with a gradual increase in temperature to -15°C (Table 1, entry 2). One of the reasons for the low yield of



SCHEME 4

Synthesis of disaccharide donors **42** and **44**. Reagents and conditions: (i) TfOH, MS AW300, CH₂Cl₂, -20°C, 7 min, 79%, only α; (ii) CAN, MeCN, benzene, H₂O, 0 °C, 10 min, 71%; and (iii) ClC(NPh)CF₃, K₂CO₃, acetone, 12 h, 60%.



SCHEME 5

Synthesis of the linear pentasaccharides **4a** and **4b**. Reagents and conditions: (i) TfOH, MS AW300, CH₂Cl₂, -20°C, 6 min, α:β = 20:1, 75%; (ii) piperidine, THF, 0 °C, 20 min, 95%; (iii) TMSOTf, MS AW300, CH₂Cl₂, -5°C, 2.5 h, only α, 55%; (iv) 1) piperidine, THF, 0 °C, 35 min; 2) NaOMe, MeOH, 12 h; and 3) H₂, Pd(OH)₂/C, HCl, MeOH, EtOAc, 5 h, 59% for the three steps; and (v) AEB, Et₃N, DMF, 12 h, 92%.


disaccharide **23**, in this case, is the removal of Fmoc from the O-6 product by triethylamine, which is used to neutralize unreacted acid after the reaction is completed (Oberli et al., 2008). This is confirmed by an increase in the yield of disaccharide **23** up to 64% when the addition of triethylamine was omitted, and the reaction mixture was immediately filtered and washed with a saturated NaHCO₃ solution (Table 1, entry 3).

The disaccharide acceptor **25** was obtained from **23** by the removal of the 2-O-allyl group with the iridium complex [Ir(COD)(PMePh₂)₂]PF₆ pre-reduced with hydrogen (Scheme 3). Glycosylation of acceptor **25** by galactofuranosyl donor **22**, previously obtained by us (B. Krylov et al., 2018), in the presence of TMSOTf, resulted in trisaccharide **28** with a high yield as a pure β-isomer. In the next step, the hydroxyl group at the C-3 atom of the non-reducing residue was recovered by hydrazine acetate in pyridine. However, in addition to the expected disaccharide **29**, we observed the formation of a migration product of pentafluorobenzoate from O-4 to O-3 (compound **29i**). Both regioisomers **29** and **29i** were successfully separated by column chromatography and found applications in the synthetic scheme.

The target trisaccharide **1a** was synthesized from the pentafluorobenzoate migration product **29i** in three steps. First, the

Fmoc-protecting group was removed with piperidine in THF. Then, without intermediate purification, benzoyl substituents were removed in the presence of sodium methylate in methanol. The following reduction of the azide group in the spacer to the amino group and the simultaneous removal of benzyl groups by treatment with sodium in liquid ammonia yielded the unprotected (1→2)-trisaccharide **1a** with a high yield of 98%. Tetrasaccharide **30** was obtained by coupling galactofuranosyl donor **22** and trisaccharide acceptor **29** with a fairly high yield of 87% and exclusively as a pure β-isomer. The sequential removal of protecting groups using a scheme similar to that described above for trisaccharide **29i** resulted in unprotected tetrasaccharide **3a**.

Unlike in trisaccharide **28**, the removal of the 3-O-levulinoyl group in disaccharide **23** did not result in the migration of the pentafluorobenzoate from O-4 to O-3. The furanosyl residue was introduced by glycosylation with donor **22**, resulting in the formation of β-(1→3)-trisaccharide **26** with an 86% yield. The removal of all protecting groups in compound **26** included (1) 2-O-deallylation (→**27**); (2) removal of 6-O-Fmoc with piperidine in THF; (3) removal of 4-O-pentafluorobenzoate and benzoyl groups with sodium methylate in methanol; and (4) hydrogenolysis on Pd(OH)₂/C in the presence of a small amount of hydrochloric acid, which prevents the methylation of the amino group of the target (1→3)-trisaccharide **2a**.



The α-(1→6)-linked galactopyranosyl chain in the synthesis of target compounds **4a** and **5a** was elongated with disaccharide donor **33** (Scheme 4). The glycosylation reaction of *p*-methoxygalactoside **15** by donor **17** in the presence of TfOH proceeded with the exclusive formation of α-isomer **33** due to the concerted action of three α-stereodirecting acyl groups at O-3, O-4, and O-6 (Baek et al., 2015). The absence of the β-isomer among the reaction products was confirmed by the NMR spectra of the untreated reaction mixture. The removal of the *p*-methoxyphenyl-protecting group of the anomeric center, followed by the addition of the *N*-phenyltrifluoroacetimidoyl-leaving group to the hemiacetal **32**, yielded disaccharide donor **33**.

Glycosylation of prespacer-containing monosaccharide **21** by donor **33** in the presence of TfOH (Scheme 5) resulted in a mixture of α- and β-isomeric trisaccharides in the ratio of 20:1. Their ratio was determined by the integration of the ¹H NMR spectrum of the reaction mixture. After the successful separation of the two isomers

by column chromatography, the desired α-product **34** was isolated with a yield of 75%. The trisaccharide acceptor **35** was obtained after the removal of 6-O-Fmoc with piperidine in THF. An attempt of a TfOH-assisted glycosylation of acceptor **35** with a disaccharide donor **33** failed. After an optimization of conditions, it was found that in the presence of TMSOTf and with an increase in temperature from -20°C to -5°C, α-pentasaccharide **36** is formed with a sufficient yield of 55% without any β-isomer admixture.

Protecting groups in pentasaccharide **36** were removed according to a standardized algorithm: first, Fmoc was removed with piperidine; then, benzoate groups were removed in the presence of sodium methylate in methanol; and, in the last step, the azide group was reduced and benzyl groups removed in the course of catalytic hydrogenolysis. Unprotected pentasaccharide **4a** was isolated by gel permeation chromatography with a 70% yield after all stages of deprotection. The ¹H NMR spectrum of the

TABLE 2 ¹³C-NMR chemical shifts (δ , ppm, D₂O, 303 K) for oligosaccharides 1a–5a.

Compound	Unit	C-1	C-2	C-3	C-4	C-5	C-6
1a	β -D-Galp-(1→2)-	109.98	82.00	77.21	83.28	71.18	63.25
	→2)- α -D-Galp-(1→6)-	99.21	77.06	69.02	69.84	71.41	61.70
	→6)- α -D-Galp-Sp	99.21	68.68	70.08	69.91	69.84	67.86
	β -D-Galp-(1→3)-	109.69	82.03	77.44	83.43	71.24	63.33
2a	→3)- α -D-Galp-(1→6)-	98.80	67.87	77.80	69.47	71.48	61.69
	→6)- α -D-Galp-Sp	99.18	68.70	70.04	69.86	69.86	67.13
3a	β -D-Galp-(1→2)-	109.85	82.14	77.40	83.26	71.31	63.21
	β -D-Galp-(1→3)-	109.58	82.05	77.72	83.62	71.31	63.34
	→2) →3)- α -D-Galp-(1→6)-	99.11	75.79	75.98	69.80	71.31	61.59
	→6)- α -D-Galp-Sp	99.19	68.68	70.08	69.88	70.01	67.76
4a	α -D-Galp-(1→6)-	98.38 ^a	68.84 ^b	70.05	70.05	71.55	61.71
	→6)- α -D-Galp-(1→6)-	98.38 ^a	68.84 ^b	70.05	68.88 ^c	69.44 ^d	67.06 ^e
	→6)- α -D-Galp-(1→6)-	98.50 ^a	68.84 ^b	70.05	68.81 ^c	69.22 ^d	67.06 ^e
	→6)- α -D-Galp-(1→6)-	98.60 ^a	68.72 ^b	70.05	68.88 ^c	69.22 ^d	67.06 ^e
	→6)- α -D-Galp-Sp	99.13	68.75 ^b	70.05	68.81 ^c	69.55	67.12 ^e
5a	α -D-Galp-(1→6)-	98.33	68.68 ^f	69.96	70.06	71.59	61.79
	→6)- α -D-Galp-(1→6)-	98.63	68.94 ^f	69.87 ^f	68.87 ^f	69.27 ^f	67.00
	β -D-Galp-(1→2)-	109.59	82.07	77.46	83.61	71.28	63.21
	β -D-Galp-(1→3)-	109.87	82.17	77.70	83.38	71.28	63.39
	→2) →3) →6)- α -D-Galp-(1→6)-	98.66	76.01	75.79	70.27	69.87 ^f	67.12
	→6)- α -D-Galp-Sp	99.19	69.96	69.16 ^b	70.13	69.96	67.59

^{a-f}The assignment is tentative within marked groups due to the overlap of signals and may be reversed.

product contains five anomeric proton signals. For each of the monosaccharide residues, α -configuration of the C-1 atom is confirmed both by spin–spin coupling constants (less than 4 Hz) and chemical shifts of the related carbon atoms (signals at 99.4, 98.9, and 98.8 ppm and two more signals at 98.7 ppm in ¹³C NMR).

The synthesis of hexasaccharide **5a** began with the removal of 6-O-Fmoc in disaccharide **23** by N-methylmorpholine in a mixture of dichloromethane and THF (Scheme 6). The ¹⁹F NMR spectrum, as well as the absence of piperidine signals in the ¹H spectrum, confirmed that the pentafluorobenzoyl group was not affected in this transformation. The TfOH-promoted glycosylation of the resulting acceptor **38** by disaccharide donor **33** was very slow and required a gradual increase in temperature from –20°C to –8°C. The low reaction rate and, accordingly, the accumulation of a large number of by-products of the destruction of the donor may be attributed to the presence of a strong electron-withdrawing PFB group in the immediate vicinity of the nucleophilic center in the acceptor. Attempts to vary the temperature regime of this reaction, as well as to change the promoter from TfOH to TMSOTf, *tert*-butyldimethylsilyl trifluoromethane sulfonate (TBDMSOTf), and C₄F₉SO₃H, were not successful. After the separation of α - and β -isomers, obtained in a ratio of 13:1 in the reaction promoted with TfOH, tetrasaccharide **39a** was isolated by HPLC with a yield of 51%.

For the synthesis of the branched hexasaccharide, we first obtained acceptor **40**, which was then reacted with donor **22**. Monofuranosylated pentasaccharide **41** was isolated with a fairly high yield of 84% and only as a β -isomer. The introduction of a second galactofuranosyl residue after the removal of the levulinoyl-protecting group from O-3 resulted in a protected hexasaccharide **43** with an 87% yield and absolute β -stereoselectivity. The target hexasaccharide **5a** was obtained after the sequential removal of Fmoc and benzoate groups and hydrogenolysis, with a total yield of 46% for the three steps. Two singlets (δ 5.19 and 5.17 ppm) corresponding to H-1 of furanose rings are observed in the ¹H NMR spectrum. Further notable are four doublets (δ 5.07–4.96 ppm) with *J* in the range 2.6–3.3 Hz, attributable to H-1 in pyranose residues of the main chain. Chemical shifts of the corresponding carbon atoms in the ¹H–¹³C HSQC spectra also confirm the configurations of the anomeric centers of all six carbohydrate residues of compound **5a** (for ¹³C-NMR data of **1a–5a**, see Table 2).

Biotinylated oligosaccharides **1b–5b** were obtained by the treatment of aminopropyl glycosides **1a–5a** with an activated biotin ester and triethylamine in DMF according to the described procedure (Tsvetkov et al., 2012). Following purification on gel TSK-40 afforded **1b–5b** in good to excellent yields. The attachment of the biotin entity was confirmed by the presence of characteristic signals

TABLE 3 ^{13}C NMR α - and β -glycosylation effects ($\Delta\delta$, ppm) of a branched galactose fragment in hexasaccharide 5a and related monoglycosylated oligosaccharides.

Glycosylation	Compound	Glycosylated Galp (A)						Glycosylating unit		
		$\Delta\delta\text{C-1}$	$\Delta\delta\text{C-2}$	$\Delta\delta\text{C-3}$	$\Delta\delta\text{C-4}$	$\Delta\delta\text{C-5}$	$\Delta\delta\text{C-6}$	$\Delta\delta\text{C-1B}$	$\Delta\delta\text{C-1C}$	$\Delta\delta\text{C-1D}$
$\beta\text{-D-Galp-(1}\rightarrow\text{2)-}^a$		-0.56	7.87	-1.33	—	—	—	7.10	—	—
$\beta\text{-D-Galp-(1}\rightarrow\text{3)-}^a$		—	-1.13	7.66	-0.17	—	—	—	6.93	—
$\alpha\text{-D-Galp-(1}\rightarrow\text{6)-}$	4a	—	—	—	—	-2.46	5.30	—	—	4.80
$\beta\text{-D-Galp-(1}\rightarrow\text{2)-}$ $\beta\text{-D-Galp-(1}\rightarrow\text{3)-}$ $\alpha\text{-D-Galp-(1}\rightarrow\text{6)-}$	5a	-0.49	7.30	5.93	0.27	-2.46	5.30	7.00	7.20	4.83

^aData from our previous paper (Dorokhova et al., 2021).

TABLE 4 Deviations from additivity ($\Delta\Delta\delta$, ppm) in the ^{13}C -NMR spectra of a branched fragment in hexasaccharide 5a.

Glycosylated Galp (A)						Glycosylating unit		
$\Delta\Delta\delta\text{C-1}$	$\Delta\Delta\delta\text{C-2}$	$\Delta\Delta\delta\text{C-3}$	$\Delta\Delta\delta\text{C-4}$	$\Delta\Delta\delta\text{C-5}$	$\Delta\Delta\delta\text{C-6}$	$\Delta\Delta\delta\text{C-1B}$	$\Delta\Delta\delta\text{C-1C}$	$\Delta\Delta\delta\text{C-1D}$
-0.07	-0.56	0.40	-0.44	0.00	0.00	-0.10	0.27	-0.03

in the ^1H NMR spectra (for NMR data of corresponding biotin conjugates, see the [Supplementary Material](#)) and by HRMS data.

NMR analysis of obtained oligosaccharides 1a–5a

The NMR spectra of oligosaccharides 1a–5a were totally assigned by applying 2D NMR experiments (Table 2. For ^1H NMR shifts, see [Supplementary Table S1](#) in [Supplementary Material](#)). The effects of glycosylation (Table 3, units are labeled A–D as in [Figure 2](#)) were calculated as the difference in the ^{13}C chemical shifts between two structures, one with and one without a particular type of glycosylation, as described before (Dorokhova et al., 2021). Upon the introduction of a glycosylating residue, the most pronounced spectral effect was observed on the glycosylated carbons, which underwent a down-field shift by 5–8 ppm (α -effect), while the resonances of the adjacent carbon atoms moved up-field to a smaller extent (β -effect) (Lipkind et al., 1988; Shashkov et al., 1988; Kochetkov et al., 1991; Gerbst et al., 2015). The C-1 of the glycosylating residue also underwent a significant down-field shift. Other carbon resonances were much less affected and were excluded from consideration. The α - and β -glycosylation effects for β -(1→2)- and β -(1→3)-galactofuranosylation measured using trisaccharides 1a and 2a agreed well with previously reported data (Dorokhova et al., 2021). The deviations from additivity in the vicinally branched fragment of hexasaccharide 5a (Table 4) were calculated as the difference between the experimental (δ_{exp}) and calculated (δ_{calc}) ^{13}C chemical shifts, where δ_{calc} was calculated by the summation of all glycosylation effects.

In spite of the presence of 2,3-vicinal branching and 1,2-*cis*-pseudobranching in hexasaccharide 5a, the good agreement between theoretical and experimental ^{13}C chemical shifts was determined (deviation from additivity did not exceed 0.56 ppm; Table 4). It suggests the independence of conformational flexibility around corresponding interunit linkages connected with the branched

Galp-residue of 5a. These suggest that the spatial similarity of 5a to the corresponding fragment within the chain of GXMGal makes 5a a reliable model for future immunological studies of *C. neoformans*.

Conclusion

In conclusion, the oligosaccharides 1a–5a and their biotinylated derivatives 1b–5b were synthesized according to the convergent scheme, achieving good to excellent yields at each step. The sequential introduction of β -galactofuranosyl residues at O-2 and/or O-3, along with the elongation of the α -(1→6)-galactopyranoside core chain, was achieved using a galactosyl donor bearing orthogonal groups: 2-O-allyl, 3-O-levulinoyl, and Fmoc group at O-6. High, nearly absolute α -stereoselectivity in each glycosylation step was achieved due to the joint stereoredirecting effects of O-protecting acyl groups in galactosyl donors, including the 4-O-pentafluorobenzoyl group. The analysis of ^{13}C NMR shifts and corresponding glycosylation effects for oligosaccharides 1a–5a confirms the spatial equivalence of synthetic hexasaccharide 5a to the corresponding branched fragment of the polysaccharide GXMGal, supporting the use of 5a as a reliable model hapten for further immunological studies of *C. neoformans*.

Data availability statement

The original contributions presented in the study are included in the article/[Supplementary Material](#), further inquiries can be directed to the corresponding author.

Author contributions

VD: investigation and writing—original draft. BK: data curation and writing—original draft. JP: conceptualization and

writing–review and editing. LM: conceptualization and writing–review and editing. VK: data curation, formal analysis, methodology, and writing–review and editing. NN: conceptualization, data curation, funding acquisition, project administration, resources, supervision, and writing–review and editing.

Funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by the Russian Science Foundation (Grant 19-73-30017-P) and Fundação de Apoio à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq).

Acknowledgments

The authors thank their colleagues A.S. Dmitrenok and A.S. Shashkov for recording NMR spectra and A.O. Chizhov for recording of HRMS spectra of the synthesized compounds.

References

- Ágoston, K., Streicher, H., and Fügedi, P. (2016). Orthogonal protecting group strategies in carbohydrate chemistry. *Tetrahedron Asymmetry* 27, 707–728. doi:10.1016/j.tetasy.2016.06.010
- Argunov, D. A., Aladysheva, U. S., Krylov, V. B., and Nifantiev, N. E. (2024). Acid-catalyzed transformation of pyranosides into furanosides as a tool for preparation of furanoside synthetic blocks. *Org. Lett.* 26, 8090–8094. doi:10.1021/acs.orglett.4c02984
- Argunov, D. A., Krylov, V. B., and Nifantiev, N. E. (2016). The use of pyranoside-into-furanoside rearrangement and controlled O(5) → O(6) benzoyl migration as the basis of a synthetic strategy to assemble (1→5)- and (1→6)-linked galactofuranosyl chains. *Org. Lett.* 18, 5504–5507. doi:10.1021/acs.orglett.6b02735
- Baek, J. Y., Kwon, H.-W., Myung, S. J., Park, J. J., Kim, M. Y., Rathwell, D. C. K., et al. (2015). Directing effect by remote electron-withdrawing protecting groups at O-3 or O-4 position of donors in glycosylations and galactosylations. *Tetrahedron* 71, 5315–5320. doi:10.1016/j.tet.2015.06.014
- Bermas, A., and Geddes-McAlister, J. (2020). Combatting the evolution of antifungal resistance in *Cryptococcus neoformans*. *Mol. Microbiol.* 114, 721–734. doi:10.1111/mmi.14565
- Calin, O., Eller, S., Hahm, H. S., and Seeberger, P. H. (2013). Total synthesis of the *Escherichia coli* O111 O-specific polysaccharide repeating unit. *Chem. – Eur. J.* 19, 3995–4002. doi:10.1002/chem.201204394
- Cato, D., Buskas, T., and Boons, G. (2005). Highly efficient stereospecific preparation of tn and TF building blocks using thioglycosyl donors and the Ph₂SO/Tf₂O promoter system. *J. Carbohydr. Chem.* 24, 503–516. doi:10.1081/CAR-200067091
- Chen, Y., Shi, Z. W., Strickland, A. B., and Shi, M. (2022). *Cryptococcus neoformans* infection in the central nervous system: the battle between host and pathogen. *J. Fungi* 8, 1069. doi:10.3390/jof8101069
- Cherniak, R., Reiss, E., Slodki, M. E., Plattner, R. D., and Blumer, S. O. (1980). Structure and antigenic activity of the capsular polysaccharide of *Cryptococcus neoformans* serotype A. *Mol. Immunol.* 17, 1025–1032. doi:10.1016/0161-5890(80)90096-6
- Cherniak, R., Reiss, E., and Turner, S. H. (1982). A galactoxylomannan antigen of *Cryptococcus neoformans* serotype A. *Carbohydr. Res.* 103, 239–250. doi:10.1016/S0008-6215(00)80686-2
- Cherniak, R., Valafar, H., Morris, L. C., and Valafar, F. (1998). *Cryptococcus neoformans* chemotyping by quantitative analysis of ¹H nuclear magnetic resonance spectra of glucuronoxylomannans with a computer-simulated artificial neural network. *Clin. Diagn. Lab. Immunol.* 5, 146–159. doi:10.1128/CDLI.5.2.146-159.1998
- Decote-Ricardo, D., LaRocque-de-Freitas, I. F., Rocha, J. D. B., Nascimento, D. O., Nunes, M. P., Morrot, A., et al. (2019). Immunomodulatory role of capsular

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

The author(s) declared that they were an editorial board member of *Frontiers*, at the time of submission. This had no impact on the peer review process and the final decision.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: <https://www.frontiersin.org/articles/10.3389/fchem.2024.1501766/full#supplementary-material>

polysaccharides constituents of *Cryptococcus neoformans*. *Front. Med.* 6, 129. doi:10.3389/fmed.2019.00129

Doering, T. L. (2009). How sweet it is! Cell wall biogenesis and polysaccharide capsule formation in *Cryptococcus neoformans*. *Annu. Rev. Microbiol.* 63, 223–247. doi:10.1146/annurev.micro.62.081307.162753

Dorokhova, V. S., Gerbst, A. G., Komarova, B. S., Previato, J. O., Previato, L. M., Dmitrenok, A. S., et al. (2021). Synthesis and conformational analysis of vicinally branched trisaccharide β-d-Galp-(1 → 2)-[β-d-Galp-(1 → 3)]-α-Galp from *Cryptococcus neoformans* galactoxylomannan. *Org. Biomol. Chem.* 19, 2923–2931. doi:10.1039/D0OB02071K

Gerbst, A. G., Krylov, V. B., Vinnitskiy, D. Z., Dmitrenok, A. S., Shashkov, A. S., and Nifantiev, N. E. (2015). ¹³C-NMR glycosylation effects in (1→3)-linked furanosyl-pyranosides. *Carbohydr. Res.* 417, 1–10. doi:10.1016/j.carres.2015.08.014

Gerbst, A. G., Ustuzhanina, N. E., Grachev, A. A., Khatuntseva, E. A., Tsvetkov, D. E., Whitfield, D. M., et al. (2001). Synthesis, nmr, and conformational studies of fucoidan fragments. III. Effect of benzoyl group at O-3 on stereoselectivity of glycosylation by 3-O- and 3,4-di-O-benzoylated 2-O-benzylfucosyl bromides. *J. Carbohydr. Chem.* 20, 821–831. doi:10.1081/CAR-100108659

Hargett, A. A., Azurmendi, H. F., Crawford, C. J., Wear, M. P., Oscarson, S., Casadevall, A., et al. (2024). The structure of a *C. neoformans* polysaccharide motif recognized by protective antibodies: a combined NMR and MD study. *Proc. Natl. Acad. Sci.* 121, e2315733121. doi:10.1073/pnas.2315733121

Heiss, C., Skowyra, M. L., Liu, H., Klutts, J. S., Wang, Z., Williams, M., et al. (2013). Unusual galactofuranose modification of a capsule polysaccharide in the pathogenic yeast *Cryptococcus neoformans*. *J. Biol. Chem.* 288, 10994–11003. doi:10.1074/jbc.M112.441998

Heiss, C., Stacey Klutts, J., Wang, Z., Doering, T. L., and Azadi, P. (2009). The structure of *Cryptococcus neoformans* galactoxylomannan contains β-d-glucuronic acid. *Carbohydr. Res.* 344, 915–920. doi:10.1016/j.carres.2009.03.003

Hettikankanamalage, A. A., Lassfolk, R., Ekholm, F. S., Leino, R., and Crich, D. (2020). Mechanisms of stereodirecting participation and ester migration from near and far in glycosylation and related reactions. *Chem. Rev.* 120, 7104–7151. doi:10.1021/acs.chemrev.0c00243

Hirose, H., Tamai, H., Gao, C., Imamura, A., Ando, H., Ishida, H., et al. (2015). Total syntheses of disulphated glycosphingolipid SB1a and the related monosulphated SM1a. *Org. Biomol. Chem.* 13, 11105–11117. doi:10.1039/C5OB01744K

James, P. G., and Cherniak, R. (1992). Galactoxylomannans of *Cryptococcus neoformans*. *Infect. Immun.* 60, 1084–1088. doi:10.1128/iai.60.3.1084-1088.1992

- Kochetkov, N. K., Lipkind, G. M., Shashkov, A. S., and Nifantiev, N. E. (1991). N.m.r. and conformational analysis of some 2,3-disubstituted methyl α -L-rhamnopyranosides. *Carbohydr. Res.* 221, 145–168. doi:10.1016/0008-6215(91)80053-P
- Komarova, B. S., Dorokhova, V. S., Tsvetkov, Y. E., and Nifantiev, N. E. (2018a). Synthesis of a biotinylated penta- α -(1 \rightarrow 6)-D-glucoside based on the rational design of an α -stereoselective glucosyl donor. *Org. Chem. Front.* 5, 909–928. doi:10.1039/C7QO01007A
- Komarova, B. S., Novikova, N. S., Gerbst, A. G., Sinitsyna, O. A., Rubtsova, E. A., Kondratyeva, E. G., et al. (2023). Combination of 3-O-levulinoyl and 6-O-trifluorobenzoyl groups ensures α -selectivity in glucosylations: synthesis of the oligosaccharides related to *Aspergillus fumigatus* α -(1 \rightarrow 3)-D-glucan. *J. Org. Chem.* 88, 12542–12564. doi:10.1021/acs.joc.3c01283
- Komarova, B. S., Orekhova, M. V., Tsvetkov, Y. E., Beau, R., Aimaniana, V., Latgé, J., et al. (2015). Synthesis of a pentasaccharide and neoglycoconjugates related to fungal α -(1 \rightarrow 3)-glucan and their use in the generation of antibodies to trace *Aspergillus fumigatus* cell wall. *Chem. – Eur. J.* 21, 1029–1035. doi:10.1002/chem.201404770
- Komarova, B. S., Orekhova, M. V., Tsvetkov, Y. E., and Nifantiev, N. E. (2014). Is an acyl group at O-3 in glucosyl donors able to control α -stereoselectivity of glycosylation? The role of conformational mobility and the protecting group at O-6. *Carbohydr. Res.* 384, 70–86. doi:10.1016/j.carres.2013.11.016
- Komarova, B. S., Tsvetkov, Y. E., and Nifantiev, N. E. (2016). Design of α -selective glycopyranosyl donors relying on remote anchimeric assistance. *Chem. Rec.* 16, 488–506. doi:10.1002/tcr.201500245
- Komarova, B. S., Wong, S. S. W., Orekhova, M. V., Tsvetkov, Y. E., Krylov, V. B., Beauvais, A., et al. (2018b). Chemical synthesis and application of biotinylated oligo- α -(1 \rightarrow 3)-D-glucosides to study the antibody and cytokine response against the cell wall α -(1 \rightarrow 3)-D-glucan of *Aspergillus fumigatus*. *J. Org. Chem.* 83, 12965–12976. doi:10.1021/acs.joc.8b01142
- Krylov, V. B., Argunov, D. A., Solovev, A. S., Petruk, M. I., Gerbst, A. G., Dmitrenok, A. S., et al. (2018). Synthesis of the tetrasaccharide related to galactomannans from *Aspergillus fumigatus* and their NMR spectral data. *Org. Biomol. Chem.* 16, 1188–1199. doi:10.1039/C7OB02734F
- Krylov, V. B., Solovev, A. S., Puchkin, I. A., Yashunsky, D. V., Antonets, A. V., Kutsevalova, O. Y., et al. (2021). Reinvestigation of carbohydrate specificity of EBCA-1 monoclonal antibody used for the detection of *Candida mannan*. *J. Fungi* 7, 504. doi:10.3390/jof7070504
- Laroussarie, A., Barycza, B., Andriamboavonjy, H., Tamigney Kenfack, M., Blériot, Y., and Gauthier, C. (2015). Synthesis of the tetrasaccharide repeating unit of the β -kdo-containing exopolysaccharide from *Burkholderia pseudomallei* and *B. cepacia* complex. *J. Org. Chem.* 80, 10386–10396. doi:10.1021/acs.joc.5b01823
- Lipkind, G. M., Shashkov, A. S., Knirel, Y. A., Vinogradov, E. V., and Kochetkov, N. K. (1988). A computer-assisted structural analysis of regular polysaccharides on the basis of ^{13}C -n.m.r. data. *Carbohydr. Res.* 175, 59–75. doi:10.1016/0008-6215(88)80156-3
- Maziarsz, E. K., and Perfect, J. R. (2016). Cryptococcosis. *Infect. Dis. Clin.* 30, 179–206. doi:10.1016/j.idc.2015.10.006
- McFadden, D. C., and Casadevall, A. (2004). Unexpected diversity in the fine specificity of monoclonal antibodies that use the same V region gene to glucuronoxylomannan of *Cryptococcus neoformans*. *J. Immunol.* 172, 3670–3677. doi:10.4049/jimmunol.172.6.3670
- Nakouzi, A., Zhang, T., Oscarson, S., and Casadevall, A. (2009). The common *Cryptococcus neoformans* glucuronoxylomannan M2 motif elicits non-protective antibodies. *Vaccine* 27, 3513–3518. doi:10.1016/j.vaccine.2009.03.089
- Nigudkar, S., and Demchenko, V. (2015). Stereocontrolled 1,2-cis-glycosylation as the driving force of progress in synthetic carbohydrate chemistry. *Chem. Sci.* 6, 2687–2704. doi:10.1039/C5SC0280J
- Oberli, M. A., Bindschädler, P., Werz, D. B., and Seeberger, P. H. (2008). Synthesis of a hexasaccharide repeating unit from *Bacillus anthracis* vegetative cell walls. *Org. Lett.* 10, 905–908. doi:10.1021/ol7030262
- Oscarson, S., Alpe, M., Svahnberg, P., Nakouzi, A., and Casadevall, A. (2005). Synthesis and immunological studies of glycoconjugates of *Cryptococcus neoformans* capsular glucuronoxylomannan oligosaccharide structures. *Vaccine* 23, 3961–3972. doi:10.1016/j.vaccine.2005.02.029
- Paccoud, O., Desnos-Ollivier, M., Cassaing, S., Boukris-Sitbon, K., Alanio, A., Bellanger, A.-P., et al. (2023). *Cryptococcus neoformans* infections differ among human immunodeficiency virus (HIV)-Seropositive and HIV-seronegative individuals: results from a nationwide surveillance program in France. *Open Forum Infect. Dis.* 11, ofad658. doi:10.1093/ofid/ofad658
- Peltier, P., Euzen, R., Daniellou, R., Nugier-Chauvin, C., and Ferrières, V. (2008). Recent knowledge and innovations related to hexofuranosides: structure, synthesis and applications. *Carbohydr. Res.* 343, 1897–1923. doi:10.1016/j.carres.2008.02.010
- Pennington, M. W., and Dunn, B. M. (1994). *Peptide synthesis protocols* (Totowa, NJ: Humana Press).
- Prabhu, A., Venot, A., and Boons, G.-J. (2003). New set of orthogonal protecting groups for the modular synthesis of heparan sulfate fragments. *Org. Lett.* 5, 4975–4978. doi:10.1021/ol0359261
- Previato, J. O., Vinogradov, E., Maes, E., Fonseca, L. M., Guerardel, Y., Oliveira, P. A. V., et al. (2017). Distribution of the O-acetyl groups and β -galactofuranose units in galactoxylomannans of the opportunistic fungus *Cryptococcus neoformans*. *Glycobiology* 27, 582–592. doi:10.1093/glycob/cww127
- Rajasingham, R., Govender, N. P., Jordan, A., Loyce, A., Shroufi, A., Denning, D. W., et al. (2022). The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis. *Lancet Infect. Dis.* 22, 1748–1755. doi:10.1016/S1473-3099(22)00499-6
- Richards, M. R., and Lowary, T. L. (2009). Chemistry and biology of galactofuranose-containing polysaccharides. *ChemBioChem* 10, 1920–1938. doi:10.1002/cbic.200900208
- Rivera, J., Feldmesser, M., Cammer, M., and Casadevall, A. (1998). Organ-dependent variation of capsule thickness in *Cryptococcus neoformans* during experimental murine infection. *Infect. Immun.* 66, 5027–5030. doi:10.1128/iai.66.10.5027-5030.1998
- Shashkov, A. S., Lipkind, G. M., Knirel, Y. A., and Kochetkov, N. K. (1988). Stereochemical factors determining the effects of glycosylation on the ^{13}C chemical shifts in carbohydrates. *Magn. Reson. Chem.* 26, 735–747. doi:10.1002/mrc.1260260904
- Skelton, M. A., Cherniak, R., Poppe, L., and van Halbeek, H. (1991a). Structure of the de-O-acetylated glucuronoxylomannan from *Cryptococcus neoformans* serotype D, as determined by 2D NMR spectroscopy. *Magn. Reson. Chem.* 29, 786–793. doi:10.1002/mrc.1260290808
- Skelton, M. A., van Halbeek, H., and Cherniak, R. (1991b). Complete assignment of the ^1H - and ^{13}C -n.m.r. spectra of the O-deacetylated glucuronoxylomannan from *Cryptococcus neoformans* serotype B. *Carbohydr. Res.* 221, 259–268. doi:10.1016/0008-6215(91)80062-R
- Tefsen, B., Ram, A. F., van Die, I., and Routier, F. H. (2012). Galactofuranose in eukaryotes: aspects of biosynthesis and functional impact. *Glycobiology* 22, 456–469. doi:10.1093/glycob/cwr144
- Tokatly, A. I., Vinnitskiy, D. Z., Ustuzhanina, N. E., and Nifantiev, N. E. (2021). Protecting groups as a factor of stereocontrol in glycosylation reactions. *Russ. J. Bioorg. Chem.* 47, 53–70. doi:10.1134/S1068162021010258
- Tsvetkov, Y. E., Burg-Roderfeld, M., Loers, G., Arda, A., Sukhova, E. V., Khatuntseva, E. A., et al. (2012). Synthesis and molecular recognition studies of the HNK-1 trisaccharide and related oligosaccharides. The specificity of monoclonal anti-HNK-1 antibodies as assessed by surface plasmon resonance and STD NMR. *J. Am. Chem. Soc.* 134, 426–435. doi:10.1021/ja2083015
- Turco, S. J., and Pedersen, L. L. (2003). Galactofuranose metabolism: a potential target for antimicrobial chemotherapy. *Cell. Mol. Life Sci. CMLS* 60, 259–266. doi:10.1007/s00180300021
- Thijssen, M. J., van Rijswijk, M. N., Kamerling, J. P., and Vliegthart, J. F. (1998). Synthesis of spacer-containing di- and tri-saccharides that represent parts of the capsular polysaccharide of *Streptococcus pneumoniae* type 6B. *Carbohydrate. Research.* 306, 93–109. doi:10.1016/S0008-6215(97)00271-1
- Vaishnav, V. V., Bacon, B. E., O'Neill, M., and Cherniak, R. (1998). Structural characterization of the galactoxylomannan of *Cryptococcus neoformans* Cap67. *Carbohydr. Res.* 306, 315–330. doi:10.1016/S0008-6215(97)10058-1
- Vecchiarelli, A. (2000). Immunoregulation by capsular components of *Cryptococcus neoformans*. *Med. Mycol.* 38, 407–417. doi:10.1080/mmj.38.6.407.417
- Vecchiarelli, A., Pericolini, E., Gabrielli, E., Chow, S.-K., Bistoni, F., Cenci, E., et al. (2011). *Cryptococcus neoformans* galactoxylomannan is a potent negative immunomodulator, inspiring new approaches in anti-inflammatory immunotherapy. *Immunotherapy* 3, 997–1005. doi:10.2217/imt.11.86
- Villena, S. N., Pinheiro, R. O., Pinheiro, C. S., Nunes, M. P., Takiya, C. M., DosReis, G. A., et al. (2008). Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from *Cryptococcus neoformans* induce macrophage apoptosis mediated by Fas ligand. *Cell. Microbiol.* 10, 1274–1285. doi:10.1111/j.1462-5822.2008.01125.x
- Vinnitskiy, D. Z., Krylov, V. B., Ustuzhanina, N. E., Dmitrenok, A. S., and Nifantiev, N. E. (2015). The synthesis of heterosaccharides related to the fucoidan from *Chordaria flagelliformis* bearing an α -L-fucofuranosyl unit. *Org. Biomol. Chem.* 14, 598–611. doi:10.1039/C5OB02040A
- Vohra, Y., Buskas, T., and Boons, G.-J. (2009). Rapid assembly of oligosaccharides: a highly convergent strategy for the assembly of a glycosylated amino acid derived from PSGL-1. *J. Org. Chem.* 74, 6064–6071. doi:10.1021/jo901135k
- Werz, D. B. (2012). in *Chemical synthesis of carbohydrates and their surface immobilization: a brief introduction*. Editors C. Microarrays and Y. Chevotot (Totowa, NJ: Humana Press), 13–29. doi:10.1007/978-1-61779-373-8_2
- Zhang, Y., Hu, Y., Liu, S., He, H., Sun, R., Lu, G., et al. (2022). Total synthesis of *Leptinurus giganteus* glycans with antitumor activities via stereoselective α -glycosylation and orthogonal one-pot glycosylation strategies. *Chem. Sci.* 13, 7755–7764. doi:10.1039/D2SC02176E
- Zhao, Y., Ye, L., Zhao, F., Zhang, L., Lu, Z., Chu, T., et al. (2023). *Cryptococcus neoformans*, a global threat to human health. *Infect. Dis. Poverty* 12, 20. doi:10.1186/s40249-023-01073-4
- Zhu, S.-Y., and Yang, J.-S. (2012). Synthesis of tetra- and hexasaccharide fragments corresponding to the O-antigenic polysaccharide of *Klebsiella pneumoniae*. *Tetrahedron* 68, 3795–3802. doi:10.1016/j.tet.2012.03.074
- Zou, X., Qin, C., Pereira, C. L., Tian, G., Hu, J., Seeberger, P. H., et al. (2018). Synergistic glycosylation as key to the chemical synthesis of an outer core octasaccharide of *Helicobacter pylori*. *Chem. – Eur. J.* 24, 2868–2872. doi:10.1002/chem.201800049